HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats.

Abstract
Hepatic mitochondrial dysfunction is thought to play a role in the development of liver steatosis and insulin resistance, which are both common characteristics of obesity and type 2 diabetes mellitus (T2DM). It was hypothesized that the antioxidant properties of melatonin could potentially improve the impaired functions of hepatic mitochondria in diabetic obese animals. Male Zucker diabetic fatty (ZDF) rats and lean littermates (ZL) were given either melatonin (10 mg/kg BW/day) orally for 6 wk (M-ZDF and M-ZL) or vehicle as control groups (C-ZDF and C-ZL). Hepatic function was evaluated by measurement of serum alanine transaminase and aspartate transaminase levels, liver histopathology and electron microscopy, and hepatic mitochondrial functions. Several impaired functions of hepatic mitochondria were observed in C-ZDF in comparison with C-ZL rats. Melatonin treatment to ZDF rats decreases serum levels of ALT (P < 0.001), alleviates liver steatosis and vacuolation, and also mitigates diabetic-induced mitochondrial abnormalities, glycogen, and lipid accumulation. Melatonin improves mitochondrial dysfunction in M-ZDF rats by increasing activities of mitochondrial citrate synthase (P < 0.001) and complex IV of electron transfer chain (P < 0.05) and enhances state 3 respiration (P < 0.001), respiratory control index (RCR) (P < 0.01), and phosphorylation coefficient (ADP/O ratio) (P < 0.05). Also melatonin augments ATP production (P < 0.05) and diminishes uncoupling protein 2 levels (P < 0.001). These results demonstrate that chronic oral melatonin reduces liver steatosis and mitochondria dysfunction in ZDF rats. Therefore, it may be beneficial in the treatment of diabesity.
AuthorsAhmad Agil, Mazen El-Hammadi, Aroa Jiménez-Aranda, Mohamed Tassi, Walied Abdo, Gumersindo Fernández-Vázquez, Russel J Reiter
JournalJournal of pineal research (J Pineal Res) Vol. 59 Issue 1 Pg. 70-9 (Aug 2015) ISSN: 1600-079X [Electronic] England
PMID25904243 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Melatonin
Topics
  • Animals
  • Blotting, Western
  • Cell Line, Tumor
  • Diabetes Mellitus, Experimental (drug therapy, metabolism)
  • Humans
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Liver (metabolism)
  • Melatonin (therapeutic use)
  • Membrane Potential, Mitochondrial (drug effects)
  • Mitochondria (drug effects, metabolism, pathology)
  • Obesity (drug therapy, metabolism)
  • RNA Interference
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: